Dave Van Meter is the CEO of Neuspera Medical and draws on a track record of successful commercialization leadership and capital-raising experience to advance the company’s integrated sacral neuromodulation system as a next-generation treatment for urinary urge incontinence. A 30-year med-tech leader, Dave has transformed more than a dozen novel devices from concept into widely adopted therapies. He previously served as president and CEO of ophthalmic device maker Ivantis, Inc. Starting as Ivantis’ second employee, he led the company through clinical trials, FDA approval of the Hydrus® Microstent glaucoma device, and global commercialization in 30+ countries, with over $60 MM in annual revenue and profitability into a highly competitive space with entrenched incumbents — culminating in a successful $475 MM acquisition by Alcon in 2022. Earlier in his career, Dave held various roles of increasing responsibility as an early leader in the creation and growth of Abbott Vascular’s coronary and endovascular portfolio, including serving in roles such as Director of U.S. Marketing, General Manager of Coronary Technologies, and Vice President, Strategic Marketing, where he optimized global R&D investments and was responsible for the pipeline generation for a nearly $2 B global business.Between Ivantis and Neuspera, Dave recently also worked in the investment side of Medtech as a Venture Partner for Vertex Ventures, and serves on the Boards of Spyglass Pharma and Moximed.He holds an M.B.A. from the University of Notre Dame and a B.A. from Hillsdale College.